Syndax Pharmaceuticals Financials
| SNDX Stock | USD 18.82 0.48 2.49% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 7.75 | 9.9986 |
|
|
The essential information of the day-to-day investment outlook for Syndax Pharmaceuticals includes many different criteria found on its balance sheet. An individual investor should monitor Syndax Pharmaceuticals' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Syndax Pharmaceuticals.
Net Income |
|
Syndax | Select Account or Indicator |
Understanding current and past Syndax Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Syndax Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Syndax Pharmaceuticals' assets may result in an increase in income on the income statement.
The data published in Syndax Pharmaceuticals' official financial statements usually reflect Syndax Pharmaceuticals' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Syndax Pharmaceuticals. For example, before you start analyzing numbers published by Syndax accountants, it's critical to develop an understanding of what Syndax Pharmaceuticals' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Syndax Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Syndax Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Syndax Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Syndax Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Syndax Pharmaceuticals' management manipulating its earnings.
Syndax Pharmaceuticals Stock Summary
Syndax Pharmaceuticals competes with Valneva SE, Dominari Holdings, Procter Gamble, HP, and JPMorgan Chase. Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts. Syndax Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 59 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US87164F1057 |
| CUSIP | 87164F105 |
| Location | Massachusetts; U.S.A |
| Business Address | 35 Gatehouse Drive, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | NYSE Composite |
| Website | www.syndax.com |
| Phone | 781 419 1400 |
| Currency | USD - US Dollar |
You should never invest in Syndax Pharmaceuticals without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Syndax Stock, because this is throwing your money away. Analyzing the key information contained in Syndax Pharmaceuticals' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Syndax Pharmaceuticals Key Financial Ratios
Generally speaking, Syndax Pharmaceuticals' financial ratios allow both analysts and investors to convert raw data from Syndax Pharmaceuticals' financial statements into concise, actionable information that can be used to evaluate the performance of Syndax Pharmaceuticals over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Syndax Pharmaceuticals reports annually and quarterly.| Return On Equity | -0.52 | ||||
| Price To Sales | 12.67 X | ||||
| Gross Profit | 139.71 M |
Syndax Pharmaceuticals Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 63.5M | 300.6M | 449.7M | 497.2M | 612.9M | 643.5M | |
| Other Current Liab | 10.2M | 11.2M | 1.9M | 24.3M | 888K | 843.6K | |
| Net Debt | (23.7M) | (94.7M) | (201.0M) | (73.2M) | (293.8M) | (279.1M) | |
| Retained Earnings | (495.5M) | (568.6M) | (543.7M) | (693.0M) | (902.4M) | (857.3M) | |
| Accounts Payable | 6.2M | 3.5M | 5.7M | 4.4M | 17.2M | 18.1M | |
| Cash | 24.6M | 115.2M | 222.0M | 74.4M | 295.4M | 310.2M | |
| Other Current Assets | 763K | 341K | 380K | 194K | 63K | 59.9K | |
| Total Liab | 31.9M | 48.4M | 41.3M | 29.8M | 58.7M | 34.5M | |
| Total Current Assets | 62.3M | 298.9M | 448.4M | 481.3M | 580.9M | 609.9M | |
| Short Term Debt | 478K | 2.6M | 361K | 439K | 1.0M | 994.7K | |
| Common Stock | 3K | 5K | 6K | 7K | 8K | 8.4K | |
| Other Liab | 17.1M | 14.8M | 13.1M | 11.6M | 13.4M | 14.2M | |
| Net Tangible Assets | 31.6M | 252.2M | 408.4M | 467.4M | 537.6M | 564.4M | |
| Other Assets | 219K | 0.0 | 1.6M | 922K | 829.8K | 472.8K | |
| Net Receivables | 116K | 175K | 429K | 4.1M | 1.2M | 795.6K | |
| Inventory | 1.7M | 5.3M | 7.7M | (4.3M) | 2.0M | 1.6M | |
| Capital Surpluse | 492.5M | 527.1M | 820.8M | 952.0M | 1.1B | 669.6M | |
| Net Invested Capital | 31.6M | 272.3M | 428.3M | 467.4M | 554.2M | 300.3M |
Syndax Pharmaceuticals Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 1.6M | 2.4M | 1.9M | 3.1M | 208K | 197.6K | |
| Operating Income | (57.5M) | (71.4M) | 26.2M | (151.8M) | (230.0M) | (218.5M) | |
| Ebit | (57.5M) | (71.4M) | 26.2M | (151.8M) | (230.0M) | (218.5M) | |
| Research Development | 43.0M | 50.4M | 88.2M | 118.5M | 163.0M | 171.2M | |
| Ebitda | (57.4M) | (71.3M) | 26.3M | (151.7M) | (229.9M) | (218.4M) | |
| Income Before Tax | (56.0M) | (73.2M) | 24.9M | (149.3M) | (209.4M) | (198.9M) | |
| Net Income | (56.0M) | (73.1M) | 24.9M | (143.7M) | (209.4M) | (198.9M) | |
| Interest Income | 1.6M | 841K | 403K | 5.9M | 18.6M | 19.5M | |
| Net Interest Income | 1.6M | (1.5M) | (1.5M) | 2.7M | 18.4M | 19.3M |
Syndax Pharmaceuticals Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Syndax Pharmaceuticals. It measures of how well Syndax is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Syndax Pharmaceuticals brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Syndax had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Syndax Pharmaceuticals has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (9.3M) | 90.6M | 106.7M | (147.6M) | 221.1M | 232.2M | |
| Free Cash Flow | (50.6M) | (71.3M) | 29.0M | (133.9M) | (160.6M) | (152.6M) | |
| Other Non Cash Items | 359K | 816K | 187K | (2.0M) | (8.5M) | (8.0M) | |
| Net Income | (56.0M) | (73.2M) | 24.9M | (149.3M) | (209.4M) | (198.9M) | |
| End Period Cash Flow | 24.7M | 115.4M | 222.1M | 74.5M | 295.6M | 310.4M | |
| Investments | 12.8M | (142.5M) | (40.7M) | (186.2M) | (3.7M) | (3.9M) | |
| Change To Netincome | 6.0M | 9.4M | 12.9M | 14.0M | 16.1M | 8.2M |
Syndax Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Syndax Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Syndax Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Syndax Pharmaceuticals competition to find correlations between indicators driving Syndax Pharmaceuticals's intrinsic value. More Info.Syndax Pharmaceuticals is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers . At this time, Syndax Pharmaceuticals' Return On Equity is fairly stable compared to the past year. Comparative valuation analysis is a catch-all model that can be used if you cannot value Syndax Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Syndax Pharmaceuticals' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Syndax Pharmaceuticals Systematic Risk
Syndax Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Syndax Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. The Beta measures systematic risk based on how returns on Syndax Pharmaceuticals correlated with the market. If Beta is less than 0 Syndax Pharmaceuticals generally moves in the opposite direction as compared to the market. If Syndax Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Syndax Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Syndax Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Syndax Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
About Syndax Pharmaceuticals Financials
What exactly are Syndax Pharmaceuticals Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Syndax Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows. Potential Syndax Pharmaceuticals investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Syndax Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Syndax Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Syndax Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Steps to analyze Syndax Pharmaceuticals Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Syndax Pharmaceuticals is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Syndax has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Syndax Pharmaceuticals' financials are consistent with your investment objective using the following steps:- Review Syndax Pharmaceuticals' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Syndax Pharmaceuticals' liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Syndax Pharmaceuticals' financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Syndax Pharmaceuticals' stock is overvalued or undervalued.
Today, most investors in Syndax Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Syndax Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Syndax Pharmaceuticals growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Syndax Pharmaceuticals June 4, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Syndax Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Syndax Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Syndax Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Syndax Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Syndax Pharmaceuticals's daily price indicators and compare them against related drivers.
| Information Ratio | (0.12) | |||
| Maximum Drawdown | 12.52 | |||
| Value At Risk | (4.65) | |||
| Potential Upside | 3.84 |
Additional Tools for Syndax Stock Analysis
When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.